A Study of PMPA in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002180
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The purpose of this study is to see if it is safe and effective to give PMPA to HIV-infected patients. This study also examines how the body handles PMPA.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PMPA's antiviral activity against HIV-1 reverse transcriptase?
How does PMPA's safety profile compare to standard nucleoside reverse transcriptase inhibitors in HIV treatment?
Are there predictive biomarkers for PMPA response in HIV-infected patients with specific viral load subtypes?
What adverse events were observed in Gilead Sciences' Phase I/II PMPA trial and how were they managed?
How does PMPA's pharmacokinetic profile compare to other nucleotide analogs like tenofovir in HIV therapy?
Trial Locations
- Locations (2)
San Francisco Gen Hosp / AIDS Program
🇺🇸San Francisco, California, United States
Johns Hopkins Univ
🇺🇸Baltimore, Maryland, United States
San Francisco Gen Hosp / AIDS Program🇺🇸San Francisco, California, United States